Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells
Accumulating evidence suggests that galectin-3 is a histologic marker of thyroid cancer. However, the pharmacological lectin-based approach has not been well studied. In the present study, we aimed to investigate the therapeutic potential of novel galectin-3 inhibitors by treating thyroid cancer cel...
Saved in:
Main Authors: | Jie-Jen Lee, Yi-Chiung Hsu, Ying-Syuan Li, Shih-Ping Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2021/5583491 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comprehensive Analysis of the Mechanism of Anoikis in Hepatocellular Carcinoma
by: Dongqian Li, et al.
Published: (2024-01-01) -
Mouse Thyroid Gland Changes in Aging: Implication of Galectin-3 and Sphingomyelinase
by: Giovanna Traina, et al.
Published: (2017-01-01) -
An anoikis-related signature predicts prognosis and immunotherapy response in gastrointestinal cancers
by: Ruyi Liu, et al.
Published: (2025-02-01) -
Comparative analysis of galectin-1, galectin-3, and galectin-8 signatures in normal and choriocarcinoma trophoblast cell lines
by: Jovanović Krivokuća Milica, et al.
Published: (2024-01-01) -
A new signature associated with anoikis predicts the outcome and immune infiltration in nasopharyngeal carcinoma
by: Yonglin Luo, et al.
Published: (2025-02-01)